Search

everythinglearnresearchcommunity

for

Search:↓

CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

5α-reductase inhibitors can interfere with doping tests by masking banned substances.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Raltegravir may cause hair loss in some patients.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

A CCS patient with severe complications was successfully treated using combined therapies.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Cepharanthine effectively reduces Herpes Simplex Virus Type 1 by blocking certain cell pathways and promoting cell death.

Co-trimoxazole may help treat autoimmune diseases.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.

34% of patients on hepatitis C treatment had reversible skin issues.

CRISPR/Cas systems show promise for cancer treatment by targeting miRNAs, but delivery and specificity challenges remain.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.

The ACE1 gene variant doesn't affect long-COVID symptoms.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.